Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Neovasc Inc. T.NVC


Primary Symbol: NVCN

Neovasc Inc is a specialty medical device company. It develops, manufactures and markets products for the rapidly growing cardiovascular marketplace. Its products the Neovasc Reducer (Reducer), for the treatment of refractory angina, which is not currently commercially available in the United States and has been commercially available in Europe since 2015, and the Tiara, for the transcatheter treatment of mitral valve disease, which is under clinical investigation in the United States, Canada, Israel and Europe. The company earns revenue from one source, the Reducer.


NDAQ:NVCN - Post by User

Post by Barewoodon Apr 07, 2018 12:26am
247 Views
Post# 27846750

Reverse Split

Reverse SplitI see nothing indicating a reverse split. Currently there are 477.4M shares outstanding. The Company is attempting to work over these next three quarters with their current float of 17m to stay in budget operating on over 5m per quarter plus any other revenue streams. It's a wait and see kind of thing referring to any news releases coming soon, I'm sure. There are millions upon millions of people World wide with "refractory angina; quite the market potential the Reducer has with an aging population incidences are only going to get more common. 
<< Previous
Bullboard Posts
Next >>